Risks of a range of alcohol intake on hepatitis C‐related fibrosis

Alexander Monto, Keyur Patel, Alan Bostrom, Stephen Pianko, Paul Pockros, John G. McHutchison, Teresa L. Wright – 27 February 2004 – Heavy alcohol use contributes to liver disease in the setting of chronic hepatitis C virus (HCV) infection. Whether this is true for light or moderate alcohol use has not been demonstrated. Light alcohol use has survival benefits at a population level and is practiced by most patients with chronic HCV infection.

Hepatocyte growth factor induces Mcl‐1 in primary human hepatocytes and inhibits CD95‐mediated apoptosis via Akt

Henning Schulze‐Bergkamen, Dirk Brenner, Andreas Krueger, Dorothee Suess, Stefanie C. Fas, Christian R. Frey, Andreas Dax, Dorothea Zink, Peter Büchler, Martina Müller, Peter H. Krammer – 27 February 2004 – CD95 (APO‐1/Fas)‐mediated apoptosis of hepatocytes plays a central role in the pathophysiology of various human liver diseases. Hepatocyte growth factor (HGF) was shown to exert antiapoptotic functions in rodent hepatocytes. We previously showed that primary human hepatocytes (PHH) are a valuable tool for the investigation of apoptotic processes in liver cells.

Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer

Giovanna Vona, Laurence Estepa, Christophe Béroud, Diane Damotte, Frédérique Capron, Bertrand Nalpas, Alexandra Mineur, Dominique Franco, Bernard Lacour, Stanislas Pol, Christian Bréchot, Patrizia Paterlini‐Bréchot – 27 February 2004 – The clinical impact of circulating tumor cell (CTC) detection is controversial, mainly due to drawbacks of molecular approaches applied to this field. We sought to determine if the specific identification and counting of circulating tumor cells by cytomorphologic analysis has clinical usefulness.

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial

Keith D. Lindor, Kris V. Kowdley, E. Jenny Heathcote, M. Edwyn Harrison, Roberta Jorgensen, Paul Angulo, James F. Lymp, Lawrence Burgart, Patrick Colin – 27 February 2004 – No effective medical therapy is available for all patients with nonalcoholic steatohepatitis (NASH). Ursodeoxycholic acid (UDCA) has been suggested to be of benefit based on open label clinical studies. We randomized 166 patients with liver biopsy–proven NASH to receive between 13 and 15 mg/kg/d of UDCA or placebo for 2 years. End points included changes in liver test results and liver histology at 2 years of therapy.

Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: A randomized trial

Ming‐Chih Hou, Han‐Chieh Lin, Tsu‐Te Liu, Benjamin Ing‐Tieu Kuo, Fa‐Yauh Lee, Full‐Young Chang, Shou‐Dong Lee – 27 February 2004 – Bacterial infection may adversely affect the hemostasis of patients with gastroesophageal variceal bleeding (GEVB). Antibiotic prophylaxis can prevent bacterial infection in such patients, but its role in preventing rebleeding is unclear. Over a 25‐month period, patients with acute GEVB but without evidence of bacterial infection were randomized to receive prophylactic antibiotics (ofloxacin 200 mg i.v.

Subscribe to